A pilot study of pembrolizumab in elderly patients with non-small cell lung cancer

Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study - PROLONG STUDY

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061180068

Enrollment

Registered

2019-03-19

Start date

2017-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer Pembrolizumab, elderly patient, non-small cell lung cancer

Interventions

Patients will receive intravenous pembrolizumab (200 mg every 3 weeks) for 35 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ECOG PS 0 or 1 2) Non-small cell lung cancer 3) Stage IIIB or IV or recurrence 4) PD-L1 tumor proportion score of 50% or greater 5) No sensitizing EGFR mutations or ALK translocations 6) Chemotherapy naive 7) Provided written informed consent 8) With adequate organ function

Exclusion criteria

Exclusion criteria: 1) Pleural effusion, ascites or pericardial effusion requiring drainage 2) Other cancers 3) Symptomatic brain metastasis and meningitis 4) With severe complication 5) Interstitial pneumonia on CT 6) Severe drug allergy 7) Active autoimmune disease that has required systemic treatment 8) Dementia 9) Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	—

Secondary

Measure	Time frame
Objective Response Rate Disease Control Rate Overall survival Safety Quality of life	—

Contacts

Public ContactTakeshi Masuda

Hiroshima University Hospital

ta-masuda@hiroshima-u.ac.jp+81-822575196

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026